Fate Therapeutics

Fate Therapeutics Equity

The The Equity of Fate Therapeutics (FATE) as of Oct 24, 2026 is 207.18 M USD. In the previous year, The Equity was 318.73 M USD — a change of -35.00% (lower).

Equity

207.18 MUSD

YoY

-35.00%

Last updated:

In 2025, Fate Therapeutics's equity was 207.18 M USD, a -35.00% increase from the 318.73 M USD equity in the previous year.

The Fate Therapeutics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
160.47 M USD
Jan 1, 2019
244.76 M USD
Jan 1, 2020
384.45 M USD
Jan 1, 2021
678.84 M USD
Jan 1, 2022
483.94 M USD
Jan 1, 2023
368.42 M USD
Jan 1, 2024
318.73 M USD
Jan 1, 2025
207.18 M USD
The Fate Therapeutics Equity history
YEAREquityYoY
207.18 MUSD-35.00%
318.73 MUSD-13.49%
368.42 MUSD-23.87%
483.94 MUSD-28.71%
678.84 MUSD+76.58%
384.45 MUSD+57.07%
244.76 MUSD+52.53%
160.47 MUSD+107.89%
77.19 MUSD+5.52%
73.15 MUSD+92.32%
38.04 MUSD+34.22%
28.34 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fate Therapeutics Stock analysis

What does Fate Therapeutics do? Fate Therapeutics Inc is a biotechnology company specializing in the development of cell therapies. The company was founded in 2007 by four scientists who recognized the need for new therapies and treatment options. Their goal was to find new ways to promote tissue and organ regeneration and repair by harnessing the biological mechanisms within cells. Fate Therapeutics' business model is to develop and market state-of-the-art cell therapies based on human stem cells. These stem cells are typically obtained from patients' bone marrow or adipose tissue and then cultured in specialized cell cultures to prepare them for medical use. Fate Therapeutics currently offers several different products and services, including: - Cell therapies for the treatment of cancer: The company has developed a range of cell therapies aimed at boosting the immune system and mobilizing against cancer cells. These therapies are based on the method of extracting so-called T cells from the patient's blood, growing and modifying them in the lab to enhance their ability to target cancer cells. - Therapies for the treatment of genetic diseases: Fate Therapeutics has also developed cell therapies aimed at treating genetic mutations or defects. These therapies are based on the method of obtaining pluripotent stem cells (iPS cells) from the patient's blood or adipose tissue and then differentiating them into specialized cell types that can be used to repair tissue damage or correct genetic defects. - Services to support research and development: Fate Therapeutics also offers services to assist researchers in developing and testing their own cell therapies. This includes the cell cultures, devices, and assays needed to generate and analyze new cell lines. Fate Therapeutics is divided into several divisions to better manage its various business areas. These divisions include: - Research & Development: This division is responsible for conducting basic research to develop and test new cell therapies. This includes both foundational research and the clinical trials necessary to evaluate the effectiveness and safety of new therapies. - Manufacturing: This division is responsible for the large-scale production and processing of Fate Therapeutics' cell therapies. The company has multiple production facilities in the United States and internationally to ensure swift and efficient manufacturing and delivery of its therapies. - Sales & Marketing: This division is responsible for marketing and selling Fate Therapeutics' cell therapies. The company works closely with doctors, clinics, and medical facilities to ensure that therapies reach the patients who need them. Overall, Fate Therapeutics has become a global leader in the development of cell therapies. The company has made significant progress in recent years in developing new therapies and continues to work on finding innovative solutions to medical challenges. With its competent leadership and top-notch products and services, Fate Therapeutics Inc. is poised for even greater success in the future. Fate Therapeutics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Fate Therapeutics's Equity

Fate Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Fate Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Fate Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Fate Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Fate Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Fate Therapeutics stock

The Equity of Fate Therapeutics is 207.18 M USD in 2025.

The Equity of Fate Therapeutics changed from 318.73 M USD to 207.18 M USD, representing a -35.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Fate Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Fate Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fate Therapeutics

All Key Metrics — Fate Therapeutics